Lilly sets aside $1.45 billion to settle Zyprexa investigation
Executive Summary
Lilly announced it is in advanced discussions to resolve federal investigations of its marketing and promotional practices for the antipsychotic drug and will take a charge of $1.45 billion, or $1.29 per share, in the third quarter of 2008 for the settlement. The U.S. Attorney's Office for the Eastern District of Pennsylvania began its investigation five years ago. Earlier this month the company agreed to pay $62 million to settle a multi-state investigation of its Zyprexa sales and marketing practices (1"The Pink Sheet," Oct. 13, 2008, In Brief). Lilly has said that it will not settle a Zyprexa over-pricing suit brought by third party payers (2"The Pink Sheet," July 14, 2008, p. 18)
You may also be interested in...
Lilly settles state litigation over Zyprexa marketing
Lilly agrees to pay $62 million to 32 states and the District of Columbia to resolve an investigation of its promotional practices for Zyprexa (olanzapine). The company agrees not to promote the antipsychotic drug for off-label uses and to disclose its grants and payments to promotional speakers and consultants. It also agrees not to use certain statistical analyses in reporting Zyprexa trial results. The states reached a similar agreement with Merck regarding Vioxx promotions (1"The Pink Sheet," May 26, 2008, p. 22)
Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud
Lilly intends to fight rather than settle a suit by third party payers alleging the company overpriced its antipsychotic drugZyprexa (olanzapine)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”